appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Nectar Lifesciences Ltd
NECLIFE
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
High Pledged Promoter HoldingLower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Updates
Nectar Lifesciences Limited has informed the Exchange regarding 'Acquisition of Equity Shares in open market under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations )'. | Download
Nectar Lifesciences Limited has informed the Exchange regarding 'Acquisition of Equity Shares in open market under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ( PIT Regulations )'. | Download
Reply to Clarification- Financial results
The Exchange had sought clarification from Nectar Lifesciences Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. | Download
The Exchange had sought clarification from Nectar Lifesciences Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. | Download
Cash Dividend
Final • Div/Share: ₹ 0.05
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 11.45%